What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
Where is NuVasive's stock going? Where will NuVasive's stock price be in 2017?
11 analysts have issued 1-year price objectives for NuVasive's shares. Their predictions range from $57.00 to $84.00. On average, they expect NuVasive's stock price to reach $71.70 in the next twelve months.
When will NuVasive announce their earnings?
NuVasive is scheduled to release their next quarterly earnings announcement on Monday, April, 24th 2017.
What are analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
According to Zacks Investment Research, "NuVasive witnessed robust share price movement as compared to the Zacks categorised Medical Product industry in the past one month. However a disappointing estimate revision trend indicates looming concerns ahead. The company posted disappointing third-quarter results, with both earnings and revenues missing the Zacks Consensus Estimate. However, on a positive note, the company saw double-digit growth in Spinal Hardware and Surgical Support businesses. The company presently is rapidly developing technologies and services for spine surgery. Further, NuVasive recently included NSO and Biotronic NeuroNetwork which is expected to strengthen its foothold in the growing spine market. On the flip side pricing and margin pressures, reimbursement issues and competitive landscape are major downsides." (12/28/2016)
Leerink Swann analysts commented, "We view NUVA’s acquisition of its Brazilian distributor as a positive move, which increases our confidence in NUVA’s ability to achieve OUS growth targets. Yesterday, the company announced that it has entered into a definitive agreement to acquire Mega Surgical, the exclusive distributor of NUVA’s products in Brazil. Deal terms were not disclosed, as (according to mgmt.) it’s immaterial. The transaction is expected to close during 1Q16. Recall, Brazil has been a trouble spot for a number of ortho players, including NUVA over the past few quarters. For NUVA, the problem has been a bit more pronounced on the cash collection front where management indicated that, despite solid end-market trends (i.e., surgeries still getting done) it had been unable to collect payments from the region which the company indicated (in our follow-up w/ mgmt.) would have amounted to ~$1M in sales during 4Q15. Using the 4Q15 $1M commentary as an approximate run-rate, we estimate NUVA’s Brazil distributor was accounting for somewhere in the neighborhood of ~$3-4M worth of business annually (end-market generated, not necessarily cash collected)." (3/17/2016)
Who owns NuVasive stock?
NuVasive's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Champlain Investment Partners LLC (3.71%), State Street Corp (3.18%), Dimensional Fund Advisors LP (2.15%), Alyeska Investment Group L.P. (1.78%), Viking Global Investors LP (1.38%) and Thrivent Financial for Lutherans (1.18%). Company insiders that own NuVasive stock include Alexis V Lukianov, Gregory T Lucier, Jack R Blair, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles, Quentin S Blackford and Russell Powers.
Who sold NuVasive stock? Who is selling NuVasive stock?
NuVasive's stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Federated Investors Inc. PA, State Street Corp, Castleark Management LLC, Cipher Capital LP, Turner Investments LLC, Nicholas Co. Inc. WI and Ramsey Quantitative Systems. Company insiders that have sold NuVasive stock in the last year include Jason Hannon, Lesley H Howe and Matthew Link.
Who bought NuVasive stock? Who is buying NuVasive stock?
NuVasive's stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Hodges Capital Management Inc., Alyeska Investment Group L.P., Champlain Investment Partners LLC, Russell Investments Group Ltd., Guggenheim Capital LLC, Seven Eight Capital LP and Highland Capital Management LP. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran and Patrick Miles.
How do I buy NuVasive stock?
Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of NuVasive stock cost?
One share of NuVasive stock can currently be purchased for approximately $73.56.